Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Biotalys announces that it will publish its annual report and financial results for the full year of 2025 on Wednesday, 29 April 2026 at 07:00 CEST.
-
ABC Arbitrage 2025 Results¹: €25.1 m ROE 2025: 14.8% | Per share distribution 2025: €0.3 4 The Board of Directors of ABC arbitrage, presided by the Chairman Dominique Ceolin, met on March 19, 2026...
-
ABC arbitrage Résultat consolidé 20251 : 25,1 M€ ROE 2025 : 14,8 % | Distribution par action 2025 : 0,34 € Le conseil d’administration de la société ABC arbitrage s’est réuni le 19 mars 2026,...
-
BROADVIEW, Ill., March 23, 2026 (GLOBE NEWSWIRE) -- Innovative Food Holdings, Inc. (OTCQB: IVFH) (“IVFH” or the “Company”), a national seller of gourmet specialty foods, today announced an updated...
-
HOUSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Battalion Oil Corporation (NYSE American: BATL, “Battalion” or the “Company”) today announced financial and operating results for the fourth quarter of...
-
Amsterdam, 23 March 2026 EXOR REPORTS €37.1 BILLION GROSS ASSET VALUE AT END-2025 NAV per share decreased by 8.1% compared to a 5.4% increase in the MSCI World IndexPerformance was driven by...
-
Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash...
-
Revenue Growth Driving Group to Record EBITDA •Revenue of $186.5 million with organic revenue growth of 6.2%•Record Adjusted EBITDA of $45.4 million, up 17.7% year over year, achieved at a margin of...
-
A Mobilicom Tier-1 defense customer won a U.S. Department of War (DoW) Program of Record, indicating a potential production scale orders for the next 5 years Cash and cash equivalents surge 120% to...
-
Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ...